AZD8848 Single Ascending Dose Study
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 48
Summary
- Conditions
- Healthy
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Investigator)Primary Purpose: Basic Science
Participation Requirements
- Age
- Between 18 years and 50 years
- Gender
- Both males and females
Description
A Double-blind, Placebo-controlled, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Inhaled Doses of AZD8848 in Healthy Subjects
A Double-blind, Placebo-controlled, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Inhaled Doses of AZD8848 in Healthy Subjects
Tracking Information
- NCT #
- NCT01560234
- Collaborators
- Not Provided
- Investigators
- Study Director: Ajay Aggarwal AstraZeneca R&D, 35 Gatehouse Drive, MA 02451 USA Principal Investigator: James Ritter, BA,MA D Phil,BM BCh,MRCP,FRCP Quintile Drug Research Unit at Guy's Hospital Quintiles Ltd 6 Newcomen Street London SE1 1YR United Kingdom
Get Well Soon